Latest Hotspot

NMPA Approves Henlius' IND Application for Pembrolizumab Biosimilar

5 September 2024
3 min read

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the National Medical Products Administration (NMPA) has approved their investigational new drug (IND) application for the clinical trial of HLX17, a pembrolizumab biosimilar developed independently by the company. This biosimilar will target the same indications as pembrolizumab, including melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell cancer, colorectal cancer, hepatocellular carcinoma, biliary tract cancer, triple-negative breast cancer, microsatellite instability-high or mismatch repair deficient cancer, and gastric cancer, among others.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

HLX17 is a biosimilar to pembrolizumab, independently developed by Henlius following the biosimilar guiding principles set forth by the NMPA, and in accordance with the guidelines of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Studies on pharmacologic comparisons, preclinical pharmacology, pharmacodynamics, pharmacokinetics, and immunogenicity show that HLX17 has proven comparable to the reference pembrolizumab.

Immune checkpoint inhibitors have become pivotal in immunotherapy, burgeoning as a groundbreaking method against tumor cells, with their unique benefits and significant potential increasingly recognized. HLX17 is a monoclonal antibody designed to bind to the PD-1 receptor on T cells, inhibiting its interaction with PD-L1 and PD-L2. This action lifts PD-1 pathway-mediated suppression of the immune response, including the anti-tumor response, thereby reinstating T-cell immune surveillance over tumors and enhancing its anti-tumor effectiveness.

Leveraging its robust integrated antibody drug R&D platform, Henlius has accelerated the development of immunotherapies and established a diverse pipeline featuring high-potential immune checkpoints like PD-1/L1, CTLA-4, LAG-3, TIGIT, among others. These are anticipated to be effective across various indications and will create synergies with the company's in-house products and other innovative therapies.

Looking ahead, Henlius will continue to focus on unaddressed medical needs, expand its footprint in various disease areas, and commit to delivering high-quality, affordable treatments to patients worldwide.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of September 4, 2024, there are 455 investigational drugs for the PD-1 targets, including 897 indications, 467 R&D institutions involved, with related clinical trials reaching 8290, and as many as 82197 patents.

Pembrolizumab biosimilar (Henlius) is a biosimilar drug classified as a monoclonal antibody, designed to target PD-1. The drug is being developed by Shanghai Henlius Biotech, Inc., with the highest phase of development being the Investigational New Drug (IND) Application in both the global and Chinese markets.

图形用户界面, 文本, 应用程序

描述已自动生成

IgGenix Shares Findings on IGNX001 for Peanut Allergy at 2024 ASCIA Meeting
Latest Hotspot
3 min read
IgGenix Shares Findings on IGNX001 for Peanut Allergy at 2024 ASCIA Meeting
5 September 2024
IgGenix revealed promising data about its primary candidate, IGNX001. This candidate is an IgG4 monoclonal antibody therapy designed to treat peanut allergy.
Read →
Finerenone Enhances Cardiovascular Outcomes in Common Heart Failure
Latest Hotspot
4 min read
Finerenone Enhances Cardiovascular Outcomes in Common Heart Failure
5 September 2024
Finerenone significantly improved cardiovascular outcomes in adults with a prevalent form of heart failure, addressing a significant medical need.
Read →
Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, First to Slow Disability in Non-Relapsing Secondary Progressive MS
Latest Hotspot
4 min read
Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, First to Slow Disability in Non-Relapsing Secondary Progressive MS
4 September 2024
Tolebrutinib achieves main goal in HERCULES phase 3 trial, proving to be the first to reduce disability progression in non-relapsing secondary progressive multiple sclerosis.
Read →
Utilize Patsnap Chemical to Unlock the Chemical Structure and Patent Layout of Fulzerasib
Chem Structure
5 min read
Utilize Patsnap Chemical to Unlock the Chemical Structure and Patent Layout of Fulzerasib
4 September 2024
we will use the drug Fulzerasib as an example to demonstrate how to quickly obtain information about its chemical structure and patent situation using the Synapse database and Patsnap Chemical.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.